106 related articles for article (PubMed ID: 12224380)
21. Contribution of mutation at amino acid 45 of AcrR to acrB expression and ciprofloxacin resistance in clinical and veterinary Escherichia coli isolates.
Webber MA; Talukder A; Piddock LJ
Antimicrob Agents Chemother; 2005 Oct; 49(10):4390-2. PubMed ID: 16189130
[TBL] [Abstract][Full Text] [Related]
22. [Antibiotic resistance of bacterial strains in paediatric infections: there are resistance and resistance!].
Bingen E
Arch Pediatr; 2008 Oct; 15 Suppl 2():S49-52. PubMed ID: 19000854
[TBL] [Abstract][Full Text] [Related]
23. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
Pasquali F; Manfreda G
Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
[TBL] [Abstract][Full Text] [Related]
24. Phylogenetic background and virulence genotype of ciprofloxacin-susceptible and ciprofloxacin-resistant Escherichia coli strains of human and avian origin.
Graziani C; Luzzi I; Corro M; Tomei F; Parisi G; Giufre M; Morabito S; Caprioli A; Cerquetti M
J Infect Dis; 2009 Apr; 199(8):1209-17. PubMed ID: 19226230
[TBL] [Abstract][Full Text] [Related]
25. The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of pulmonary cells.
Demiralay R; Gürsan N; Erdem H
Toxicology; 2006 Feb; 219(1-3):197-207. PubMed ID: 16377052
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of bacterial adhesion by subinhibitory concentrations of antibiotics.
Vidya KC; Mallya PS; Rao PS
Indian J Med Microbiol; 2005 Apr; 23(2):102-5. PubMed ID: 15928438
[TBL] [Abstract][Full Text] [Related]
27. Polyamine effects on antibiotic susceptibility in bacteria.
Kwon DH; Lu CD
Antimicrob Agents Chemother; 2007 Jun; 51(6):2070-7. PubMed ID: 17438056
[TBL] [Abstract][Full Text] [Related]
28. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
Marangon FB; Miller D; Muallem MS; Romano AC; Alfonso EC
Am J Ophthalmol; 2004 Mar; 137(3):453-8. PubMed ID: 15013867
[TBL] [Abstract][Full Text] [Related]
29. Outbreak of ciprofloxacin-susceptible community-associated meticillin-resistant Staphylococcus aureus in a neonatal unit.
Seetulsingh P; Curtis C; Kearns AM
J Hosp Infect; 2008 Apr; 68(4):374-5. PubMed ID: 18346816
[No Abstract] [Full Text] [Related]
30. Subinhibitory concentrations of phenyl lactic acid interfere with the expression of virulence factors in Staphylococcus aureus and Pseudomonas aeruginosa clinical strains.
Chifiriuc MC; Diţu LM; Banu O; Bleotu C; Drăcea O; Bucur M; Larion C; Israil AM; Lazăr V
Roum Arch Microbiol Immunol; 2009; 68(1):27-33. PubMed ID: 19507624
[TBL] [Abstract][Full Text] [Related]
31. Interference of sub-inhibitory concentrations of gatifloxacin on various determinants of bacterial virulence.
Dal Sasso M; Bovio C; Culici M; Braga PC
J Chemother; 2002 Oct; 14(5):473-82. PubMed ID: 12462427
[TBL] [Abstract][Full Text] [Related]
32. [Survey on drug resistance to ciprofloxacin in common pathogenic bacteria].
Zhang YL; Geng SN; Lai FC; Wang NP
Di Yi Jun Yi Da Xue Xue Bao; 2002 Apr; 22(4):378-9. PubMed ID: 12390755
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial activity and interference of tobramycin and chloramphenicol on bacterial adhesion to intraocular lenses.
Drago L; De Vecchi E; Nicola L; Gismondo MR
Drugs Exp Clin Res; 2003; 29(1):25-35. PubMed ID: 12866361
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Gualco L; Schito AM; Schito GC; Marchese A
Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
[TBL] [Abstract][Full Text] [Related]
35. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
36. [Investigation of the effects of efflux pump inhibitors on ciprofloxacin MIC values of high level fluoroquinolone resistant Escherichia coli clinical isolates].
Coban AY; Birinci A; Ekinci B; Durupinar B
Mikrobiyol Bul; 2004; 38(1-2):21-5. PubMed ID: 15293898
[TBL] [Abstract][Full Text] [Related]
37. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
[TBL] [Abstract][Full Text] [Related]
38. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
39. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.
Cazzola M; Page C; Rogliani P; Calzetta L; Matera MG
Drugs; 2020 Nov; 80(17):1799-1809. PubMed ID: 33025535
[TBL] [Abstract][Full Text] [Related]
40. [Synthesis and antibacterial activity of 5-amino-6, 8-difluoro-1-(5-fluoro-2-pyridyl)-7-(3-methyl-1-piperazinyl)-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid and its analogues].
Liu JY; Wei YG; Guo HY
Yao Xue Xue Bao; 2001 Jun; 36(6):419-22. PubMed ID: 12585124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
